4 - Polaryx Therapeutics, Inc. (0002075320) (Issuer)

4 - Polaryx Therapeutics, Inc. (0002075320) (Issuer)

Maxim Group initiated coverage of Polaryx Therapeutics with a rating of Buy and set a new price target of $10.00

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia. "The NTSAD Annual Family Conference is an important opportunity to connect directly with the families and advocates at the heart of the rare disease community," said Alex Yang, J.D., LL.M., Chief Executive Officer of Polaryx Therapeutics. "These interactions

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). Following the March 2026 grant of FTD to PLX-200 in treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), PLX-200 now holds FTD for all four prospective indications to be studied

PARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as a Diamond honoree for Excellence in Pediatric Care. Polaryx was recognized for its innovative and scalable approach to treating lysosomal storage disorders (LSDs), a group of rare genetic diseases that cause progressive neurological decline and early mortality. Rather than developing therapies for individual conditions in isolation, the company is advancing a pl

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announces that members of the executive team will be participating in the 25th Annual Needham Virtual Healthcare Conference. Format: Polaryx management will host one-on-one investor meetings as well as a group presentation Dates: One‑on‑one meetings: Monday, April 13, 2026 through Thursday, April 16, 2026 Group presentation: Thursday, April 16, 2026 at 10:15 a.m. ET To schedule a meeting, please contact your Needham & Company, LLC representative. Live web

Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders ("LSDs"), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). The Fast Track program is designed to facilitate and expedite the review of therapies intended to treat serious or life-threatenin

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announces its participation in two upcoming events supporting the Krabbe disease community. These events reflect Polaryx's ongoing commitment to advancing research and strengthening engagement with patients, caregivers, and clinicians. 2026 Krabbe Translational Research Network Members of the Polaryx executive team, including Dr. Lisa Bollinger, Chief Medical Officer, Dr. Shrijay Vijayan, Chief Scientific and Business Development Officer, and Dr. Minsu Kang,

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers. "On Rare Disease Day, Polaryx proudly stands alongside the rare disease community - patients, families, caregivers, researchers, and advocacy partners to underscore the urgent need for new and transformative treatments," said Alex Yang, Chairman and Chief Executive Officer of Polaryx Therapeutics, Inc. "We are deeply committed to raisi

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announces it has selected a leading contract research organization (CRO) for SOTERIA, a phase 2, open-label, single-arm trial designed to evaluate the safety, tolerability, and clinical activity of Polaryx's lead candidate, PLX-200, across four different LSDs. "Our selection of a CRO partner marks an important milestone for us as we continue to advance the clinical development of SOTERIA and move closer to the clinic," said Lisa Bollinger, M.D., Chief Medical O

PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announced that the late-breaking presentation of new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, was given on February 6, 2026 in San Diego, Calif. Key Findings and Scientific Perspective At the Contemporary Forum, Late-breaking Science and the Rapid Fire Competition, Shrijay Vijayan, Ph.D., MBA, Polaryx Therapeutics' Chief Scientific and Business Development Offic

PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), today announces the appointments of Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to Polaryx's Board of Directors, effective January 29, 2026. In addition, Andrew O ceased serving as a member of the Board effective on the same date. Polaryx believes the addition of Dr. Berger, Mr. Braun, and Dr. Ryan brings valuable expertise across scientific research, clinical development,

PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), today announces the appointments of Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to Polaryx's Board of Directors, effective January 29, 2026. In addition, Andrew O ceased serving as a member of the Board effective on the same date. Polaryx believes the addition of Dr. Berger, Mr. Braun, and Dr. Ryan brings valuable expertise across scientific research, clinical development,